Health Technologies

Curi Bio appoints Nicholas A. Geisse, Ph.D as CEO

Curi Bio, the developer of human stem cell-based platforms for drug discovery, has announced the appointment of Nicholas A. Geisse, Ph.D. as CEO, effective immediately.

Dr Geisse had served as the company’s CSO since 2017.

During that time, Dr Geisse was responsible for guiding the company’s scientific strategy and the commercialisation of its next-generation products designed to improve the predictive power of in vitro cell-based assays.

Dr Geisse succeeds Michael Cho, J.D., who will continue to work for the company in a role focused on corporate strategy and legal issues.

Curi Bio co-founder and chief business officer, Elliot Fisher, said:

“Nick has been essential to Curi Bio’s rapid growth since he joined the company six years ago.

“I have full confidence in Nick’s ability to continue delivering strong leadership as we build on our successes and tackle new challenges.

“Nick has shown a clear commitment to excellence as we strive to achieve a very aggressive growth trajectory at Curi Bio.”

Curi Bio’s preclinical discovery platform combines human stem cells, systems and data to accelerate medicine discovery.

Its Curi Engine is a bioengineered platform that integrates human iPSC-derived cell models, tissue-specific biosystems, and AI/ML-enabled phenotypic screening data.

Curi Bio’s suite of human stem cell-based products and services enable scientists to build more mature and predictive human iPSC-derived tissues—with a focus on cardiac, musculoskeletal and neuromuscular models—for the discovery, safety testing and efficacy testing of new drugs in development.

Dr Geisse said:

“I am honoured and humbled to lead this extraordinary team of world-class scientists and engineers into Curi Bio’s next growth phase as we doggedly pursue our mission to accelerate the development of next-generation medicines.

“I am looking forward to the opportunity to cultivate additional partnerships and client relationships and to build on our incredible momentum.”

Michael Cho added:

“It has been an honour to lead this company and to work with such talented and dedicated colleagues over the past seven years.

“I am proud to announce Nick as my successor; he has shown exceptional leadership for our science and product development teams and brings a deep understanding of our values and mission.

“His broad experience was critical in the development of the Mantarray 3D engineered muscle tissue platform and he has a proven track record of delivering results for our stakeholders.”

You may also like

Health Technologies

Accelerating Strategies Around Internet of Medical Things Devices

  • December 22, 2022
IoMT Device Integration with the Electronic Health Record Is Growing By their nature, IoMT devices are integrated into healthcare organizations’
Health Technologies

3 Health Tech Trends to Watch in 2023

Highmark Health also uses network access control technology to ensure computers are registered and allowed to join the network. The